T2 Biosystems Stock Net Income
| TTOO Stock | USD 0 0.0007 46.67% |
As of the 13th of February 2026, T2 Biosystems owns the market risk adjusted performance of (1.07), and Standard Deviation of 161.82. In connection with fundamental indicators, the technical analysis model makes it possible for you to check timely technical drivers of T2 Biosystems, as well as the relationship between them.
T2 Biosystems' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing T2 Biosystems' valuation are provided below:T2 Biosystems does not at this moment have any fundamental measures for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. TTOO |
T2 Biosystems 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to T2 Biosystems' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of T2 Biosystems.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in T2 Biosystems on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding T2 Biosystems or generate 0.0% return on investment in T2 Biosystems over 90 days. T2 Biosystems is related to or competes with Gilead Sciences, Sanofi ADR, Amgen, Merck, and Novo Nordisk. T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United ... More
T2 Biosystems Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure T2 Biosystems' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess T2 Biosystems upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 45.62 | |||
| Information Ratio | 0.1768 | |||
| Maximum Drawdown | 1185.0 | |||
| Value At Risk | (81.82) | |||
| Potential Upside | 100.0 |
T2 Biosystems Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for T2 Biosystems' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as T2 Biosystems' standard deviation. In reality, there are many statistical measures that can use T2 Biosystems historical prices to predict the future T2 Biosystems' volatility.| Risk Adjusted Performance | 0.1539 | |||
| Jensen Alpha | 30.54 | |||
| Total Risk Alpha | 14.58 | |||
| Sortino Ratio | 0.6269 | |||
| Treynor Ratio | (1.08) |
T2 Biosystems February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1539 | |||
| Market Risk Adjusted Performance | (1.07) | |||
| Mean Deviation | 65.65 | |||
| Semi Deviation | 25.73 | |||
| Downside Deviation | 45.62 | |||
| Coefficient Of Variation | 564.16 | |||
| Standard Deviation | 161.82 | |||
| Variance | 26184.26 | |||
| Information Ratio | 0.1768 | |||
| Jensen Alpha | 30.54 | |||
| Total Risk Alpha | 14.58 | |||
| Sortino Ratio | 0.6269 | |||
| Treynor Ratio | (1.08) | |||
| Maximum Drawdown | 1185.0 | |||
| Value At Risk | (81.82) | |||
| Potential Upside | 100.0 | |||
| Downside Variance | 2081.53 | |||
| Semi Variance | 661.98 | |||
| Expected Short fall | (133.06) | |||
| Skewness | 5.35 | |||
| Kurtosis | 31.82 |
T2 Biosystems Backtested Returns
T2 Biosystems is out of control given 3 months investment horizon. T2 Biosystems retains Efficiency (Sharpe Ratio) of 0.19, which indicates the company had a 0.19 % return per unit of price deviation over the last 3 months. We were able to break down and interpolate data for twenty-seven different technical indicators, which can help you to evaluate if expected returns of 29.73% are justified by taking the suggested risk. Use T2 Biosystems standard deviation of 161.82, and Market Risk Adjusted Performance of (1.07) to evaluate company specific risk that cannot be diversified away. T2 Biosystems holds a performance score of 14 on a scale of zero to a hundred. The firm owns a Beta (Systematic Risk) of -26.46, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning T2 Biosystems are expected to decrease by larger amounts. On the other hand, during market turmoil, T2 Biosystems is expected to outperform it. Use T2 Biosystems information ratio and the relationship between the value at risk and period momentum indicator , to analyze future returns on T2 Biosystems.
Auto-correlation | 0.00 |
No correlation between past and present
T2 Biosystems has no correlation between past and present. Overlapping area represents the amount of predictability between T2 Biosystems time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of T2 Biosystems price movement. The serial correlation of 0.0 indicates that just 0.0% of current T2 Biosystems price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.27 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, T2 Biosystems reported net income of (50.08 Million). This is 114.67% lower than that of the Biotechnology sector and 128.93% lower than that of the Health Care industry. The net income for all United States stocks is 108.77% higher than that of the company.
TTOO Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses T2 Biosystems' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of T2 Biosystems could also be used in its relative valuation, which is a method of valuing T2 Biosystems by comparing valuation metrics of similar companies.T2 Biosystems is currently under evaluation in net income category among its peers.
TTOO Fundamentals
| Return On Equity | -6.22 | |||
| Return On Asset | -0.9 | |||
| Operating Margin | (4.91) % | |||
| Current Valuation | 21.91 M | |||
| Shares Outstanding | 21.04 M | |||
| Shares Owned By Insiders | 10.17 % | |||
| Shares Owned By Institutions | 73.51 % | |||
| Number Of Shares Shorted | 826.91 K | |||
| Price To Earning | (2.04) X | |||
| Price To Book | 14.50 X | |||
| Price To Sales | 0.69 X | |||
| Revenue | 7.19 M | |||
| Gross Profit | (24.77 M) | |||
| EBITDA | (43.88 M) | |||
| Net Income | (50.08 M) | |||
| Cash And Equivalents | 13.21 M | |||
| Cash Per Share | 1.87 X | |||
| Total Debt | 49.5 M | |||
| Debt To Equity | 6.64 % | |||
| Current Ratio | 1.87 X | |||
| Book Value Per Share | (6.91) X | |||
| Cash Flow From Operations | (48.14 M) | |||
| Short Ratio | 1.26 X | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 113 | |||
| Beta | 0.38 | |||
| Market Capitalization | 10.48 M | |||
| Total Asset | 34.8 M | |||
| Retained Earnings | (584.3 M) | |||
| Working Capital | (30.96 M) | |||
| Current Asset | 77.78 M | |||
| Current Liabilities | 18.54 M | |||
| Net Asset | 34.8 M |
About T2 Biosystems Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze T2 Biosystems's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of T2 Biosystems using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of T2 Biosystems based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with T2 Biosystems
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if T2 Biosystems position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in T2 Biosystems will appreciate offsetting losses from the drop in the long position's value.Moving together with TTOO Pink Sheet
| 0.74 | ORGN | Origin Materials Earnings Call This Week | PairCorr |
Moving against TTOO Pink Sheet
| 0.85 | BA | Boeing | PairCorr |
| 0.82 | AA | Alcoa Corp | PairCorr |
| 0.77 | INTC | Intel | PairCorr |
| 0.76 | XOM | Exxon Mobil Corp Aggressive Push | PairCorr |
| 0.76 | DD | Dupont De Nemours | PairCorr |
The ability to find closely correlated positions to T2 Biosystems could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace T2 Biosystems when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back T2 Biosystems - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling T2 Biosystems to buy it.
The correlation of T2 Biosystems is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as T2 Biosystems moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if T2 Biosystems moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for T2 Biosystems can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in TTOO Pink Sheet
T2 Biosystems financial ratios help investors to determine whether TTOO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in TTOO with respect to the benefits of owning T2 Biosystems security.